ArticleCancer discovery2020
Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System.
Article in Cancer discovery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 481 papers, 20 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
481 citing papers in PubMed, 20 syntheses or guidelines pooled it, 800 citations in OpenAlex.
- Guideline
- Risk assessment and clinical implications of COVID-19 in multiple myeloma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Mortality of COVID-19 in patients with hematological malignancies versus solid tumors: a systematic literature review and meta-analysis.Clinical and experimental medicine · 2023Pooled it
- Predictors of clinical evolution of SARS-CoV-2 infection in hematological patients: A systematic review and meta-analysis.Hematological oncology · 2023Pooled it
- Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.PloS one · 2023Pooled it
- Are patients with cancer at higher risk of COVID-19-related death? A systematic review and critical appraisal of the early evidence.Journal of cancer policy · 2022Pooled it
- Methodological Considerations on COVID-19 Mortality in Cancer Patients: A Systematic Review and Meta-Analysis.JNCI cancer spectrum · 2022Pooled it
- Comprehensive adjusted outcome data are needed to assess the impact of immune checkpoint inhibitors in cancer patients with COVID-19: Results of a systematic review and meta-analysis.Reviews in medical virology · 2022Pooled it
- COVID-19 mRNA Vaccine in Patients With Lymphoid Malignancy or Anti-CD20 Antibody Therapy: A Systematic Review and Meta-Analysis.Clinical lymphoma, myeloma & leukemia · 2022Pooled it
- Case fatality rate of the adult in-patients with COVID-19 and digestive system tumors: A systematic review and meta-analysis.Medicine · 2022Pooled it
- Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis.JAMA network open · 2022Pooled it
- Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis.Journal of clinical laboratory analysis · 2022Pooled it
- Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report.Journal of medical case reports · 2022Pooled it
- Pooled it
- Pooled it
- Pooled it
- Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis.BMJ open · 2022Pooled it
- Serologic response following SARS-COV2 vaccination in patients with cancer: a systematic review and meta-analysis.Journal of hematology & oncology · 2022Pooled it
- A Systematic Review Assessing the Underrepresentation of Cancer Patients in COVID-19 Trials.Acta haematologica · 2022Pooled it
- Does prior exposure to immune checkpoint inhibitors treatment affect incidence and mortality of COVID-19 among the cancer patients: The systematic review and meta-analysis.International immunopharmacology · 2021Pooled it
421 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
19 authors at 2 institutions in 1 country.
Funding
Abstract
Patients with cancer are presumed to be at increased risk from COVID-19 infection-related fatality due to underlying malignancy, treatment-related immunosuppression, or increased comorbidities. A total of 218 COVID-19-positive patients from March 18, 2020, to April 8, 2020, with a malignant diagnosis were identified. A total of 61 (28%) patients with cancer died from COVID-19 with a case fatality rate (CFR) of 37% (20/54) for hematologic malignancies and 25% (41/164) for solid malignancies. Six of 11 (55%) patients with lung cancer died from COVID-19 disease. Increased mortality was significantly associated with older age, multiple comorbidities, need for ICU support, and elevated levels of D-dimer, lactate dehydrogenase, and lactate in multivariate analysis. Age-adjusted CFRs in patients with cancer compared with noncancer patients at our institution and New York City reported a significant increase in case fatality for patients with cancer. These data suggest the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population. SIGNIFICANCE: COVID-19 in patients with cancer is associated with a significantly increased risk of case fatality, suggesting the need for proactive strategies to reduce likelihood of infection and improve early identification in this vulnerable patient population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.